HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof

US7871625B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• David Chien · Emeryville, US
• Doris Coit · Petaluma, US
• Carlos George-Nascimento · Walnut Creek, US
• Sansan Lin · Albany, US
• Angelica Medina-Selby · San Francisco, US
• Laura Tandeske · San Leandro, US

Key dates

• Filing date: Aug 26, 2005
• Grant date: Jan 18, 2011
• Expiry date: Feb 24, 2026

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.